$SLGN

Silgan (SLGN) Q2 2026 Earnings Call Transcript

Silgan (SLGN) held its Q2 2026 earnings call, reporting net sales of about $1.6 billion, up 7% year over year, and adjusted EPS of $0.98. Adjusted EPS was below the prior year due to lower adjusted EBIT. The company confirmed 2026 adjusted EPS guidance of $3.73 to $3.93 and gave Q3 2026 adjusted EPS guidance of $1.21 to $1.31.

Original reporting
Published Jul 30, 2026, 3:15 AM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Jul 30, 2026, 4:25 AM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Silgan (SLGN) Q2 2026 Earnings Call Transcript — source image
Decision brief

The 30-second read

$SLGNBullishMed
01

Why it matters

The key tradable inputs are the Q3 2026 adjusted EPS range ($1.21 to $1.31) and the confirmed FY 2026 adjusted EPS range ($3.73 to $3.93), alongside stated assumptions for EBIT growth, interest expense, tax rate, and segment volume growth.

02

Market read

Guidance ranges and segment volume/margin drivers can move SLGN expectations for Q3 and influence how investors underwrite 2H 2026 margins and growth.

03

What to watch

The call emphasizes pass-through and cost recovery actions; traders may want to monitor whether raw-material inflation reverses faster than pricing power, and whether restructuring-related volume exits create lumpy quarter-to-quarter comparisons.

Relevance 8/10Novelty 7/10Timing: ahead of Q3 2026 trading, using newly provided Q3 adjusted EPS range and confirmed FY outlook

Background

Silgan’s Q2 2026 earnings call discusses segment performance (Dispensing and Specialty Closures, Metal Containers, Custom Containers) and provides updated guidance for Q3 and confirmation for FY 2026.

Company-level read

Ticker impact

$SLGNBullishMedium confidence
Context

Silgan guided Q3 2026 adjusted EPS to $1.21 to $1.31 and confirmed full-year 2026 adjusted EPS $3.73 to $3.93.

Expected impact

Likely supportive for SLGN if investors view the Q3 range and confirmed FY EPS as credible despite Brazil softness and raw-material volatility.

Evidence & confidence

The article includes explicit adjusted EPS ranges for Q3 and FY, and explains key offsets (cost pass-through, mix, Brazil unit volume decline, restructuring exit impacts).

Market effects

Signals resilience in consumer packaging demand with cost pass-through and volume normalization dynamics across dispensing, specialty closures, and metal containers.

Brazil softness is explicitly cited as a headwind to unit volumes and mix in Q2, relevant for regional demand expectations.

Highlights ongoing sensitivity to steel, aluminum, and crude-oil-linked raw material volatility, relevant to packaging supply-chain cost assumptions.

Counterpoint

Confirmed FY EPS may already be priced in, while segment mix headwinds (Brazil and container mix) could reappear and pressure margins later in 2H.

Key entities

  • Silgan

    Consumer packaging manufacturer reporting Q2 2026 results and issuing Q3 and FY 2026 adjusted EPS guidance.

  • Dispensing and Specialty Closures

    Segment where organic volume mix is expected to grow low to mid-single digits in 2026, with Brazil softness cited in Q2.

  • Metal Containers

    Segment expected to grow low single digits in volumes in 2026, driven by pet food growth and stable human food volumes.

  • Custom Containers

    Segment volumes expected comparable to prior year after restructuring-related exits, with second-half volumes higher on a comparable basis.

Related articles

$SLGNMed

Silgan Holdings Inc. Q2 2026 Earnings Call Summary

Strategic Performance Drivers Management attributed Q2 performance to strong execution in high-value segments like fine fragrance and wet pet food, which helped offset geopolitical and inflationary headwinds. Dispensing and Specialty Closures (DSC) faced a 15% volume decline in Brazil due to inflationary market conditions, though management views this as a temporary market dynamic rather than a loss of share.

$SLGNMed

Silgan Q2 Earnings Call Highlights

Fabry said the combination of Brazil volume weakness and less favorable mix reduced second-quarter results by about $5 million. Despite that impact, adjusted EBIT in the segment was comparable with the prior year as favorable price over cost offset the volume and mix pressure. Greenlee highlighted continued strong growth in fine-fragrance dispensing products, particularly in Europe.

$SLGNMed

Silgan Q2 profit slips despite higher sales

Silgan has posted a net income of $75.8m for the second quarter (Q2) of 2026, down from $89m in the same period of 2025. Quarterly sales reached $1.64bn, an increase of $104.1m, or 7%, from a year earlier. Discover B2B Marketing That Performs Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.

$SLGNMed

SILGAN HOLDINGS INC (SLGN): Results of Operations and Financial Condition

SILGAN HOLDINGS INC (SLGN) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 a991_63026.htm EX-99.1 Document Silgan Holdings Inc. Exhibit 99.1 SILGAN ANNOUNCES SECOND QUARTER 2026 RESULTS H ighlights • Achieved high single digit volume growth in dispensing products for fragrance markets • Delivered high single digit volume growth in metal contai

$ADNTMed

Adient misses earnings estimates despite stronger-than-expected revenue

Adient (NYSE:ADNT) reported Q3 adjusted EPS of $0.48, below the $0.57 consensus, while revenue rose to $3.93B versus a $3.7B forecast. The company cited about $32M in temporary headwinds and operational inefficiencies. Adient kept FY2026 guidance, expecting ~$15B revenue, and reported GAAP net income of $25M. Shares were down ~0.9% premarket.